| Literature DB >> 30012436 |
Jordan Shapiro1, Jessica Bernica2, Ruben Hernaez3.
Abstract
Global prevalence of irritable bowel syndrome (IBS) is between 7% and 21%.1 Pathogenesis of IBS symptoms such as pain, altered bowel habits, and bloating is multifactorial, with central and peripheral mechanisms serving as targets for treatments.2 Probiotics have been studied for the treatment of IBS and are well tolerated and safe.3.Entities:
Mesh：
Year: 2018 PMID： 30012436 DOI： 10.1016/j.cgh.2018.07.010
Source DB: PubMed Journal: Clin Gastroenterol Hepatol ISSN： 1542-3565 Impact factor: 11.382